LONDON - Ark Therapeutics plc made significant advances in two of its programs, getting an FDA go-ahead for the Phase III trial of Trinam, a gene-based therapy for preventing blood vessels blocking in vascular access grafts, and securing approval for a European Phase III pilot study of Vitor in treating cancer cachexia. (BioWorld International)